Karyopharm Therapeutics Announces 15 Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models at the American Association for Cancer Research (AACR) Meeting  
3/26/2013 10:47:45 AM

NATICK, Mass., March 26, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces fifteen (15) poster presentations covering its Selective Inhibitors of Nuclear Export (SINE), oral small molecule XPO1/CRM1 antagonists, at the AACR meeting on April 6 – 13, 2013, in Washington DC. Karyopharm's lead oral XPO1 inhibitor KPT-330 is currently in Phase 1 testing in adult patients with advanced hematologic and solid tumors (NCT01607892, NCT01607905). Karyopharm's related oral XPO1 inhibitor KPT-335 is currently in a potentially pivotal study in dogs with spontaneous non-Hodgkin's lymphomas.